Policy Lab

This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin Lymphoma (HL) in patients with significant comorbidities who are ineligible to be treated with standard chemotherapy

This trial is no longer recruiting participants. Please visit https://clinicaltrials.gov/study/NCT01716806 for more information

Trial ID: NCT01716806

Trial Details

Please visit https://clinicaltrials.gov/study/NCT01716806 for more information.

Estimated Enrollment

This trial is no longer recruiting Participants

Phase

2

Eligibility Criteria

Participants must:

This study is no longer recruiting participants. Please visit https://clinicaltrials.gov/study/NCT01716806 for more information.

Participants must not:

This study is no longer recruiting participants. Please visit https://clinicaltrials.gov/study/NCT01716806 for more information.

What Will Happen in This Study

Please visit https://clinicaltrials.gov/study/NCT01716806 for more information.

Frequently Asked Questions (FAQs)